WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Anthem Biosciences Private Limited
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
TheDailyTimes | April 15, 2020
Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...
Industrial Impact
Persephone Biosciences | July 20, 2022
Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...
Industry Outlook
PRNewswire | July 10, 2023
Poseida Therapeutics, Inc. a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being devel...
Precision Virologics | September 23, 2020
Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...
Medical
Whitepaper
Cell and Gene Therapy, Medical
Research, Medical
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE